Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.23.3
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 17, 2019
Nov. 30, 2022
Jan. 31, 2018
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized       $ 3,762 $ 3,891 $ 9,550 $ 15,634
Global Blood Therapeutics | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial period of research term 3 years            
Additional extension period for research term upon mutual agreement 1 year            
Upfront payment receivable $ 20,000            
Additional extension period for research term   1 year       1 year  
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses 40,000            
Research agreement additional consideration           $ 7,100  
Deferred revenue, short-term       100   100  
Estimated transaction price       54,600   54,600  
Total transaction price 60,000            
Upfront non-refundable and non-creditable payment 20,000            
Reimbursable costs 40,000            
Revenue recognized       3,800 3,700 $ 9,500 14,400
Effective date of termination           Oct. 16, 2023  
Milestone-based payment receivable $ 0            
Global Blood Therapeutics | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Period of extension of initial research term 2 years            
Incyte              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized       $ 0 $ 200 $ 0 $ 1,200
Incyte | Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Aggregate purchase price     $ 10,000        
Shares issued     79,302        
Share price (in dollars per share)     $ 126.1        
Premium to volume-weighted sale price of shares (as a percent)     30.00%        
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares     15 days        
Incyte | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price           12,800  
Upfront non-refundable and non-creditable payment           2,500  
Up-front consideration     $ 10,000        
Up-front consideration, cash     2,500        
Up-front consideration, pre-paid research funding     $ 7,500        
Prepaid research amount           7,500  
Premium paid on equity investment           2,300  
Collaboration agreement additional consideration incurred           $ 500